Virtus LifeSci Biotech Products ETF Rating $87.16 0.00 (0.00%) As of 06/12/2026 04:10 PM Eastern Add Compare Share Share Ratings Stock AnalysisChartHoldingsOwnershipRatingsShort InterestBuy This Stock Virtus LifeSci Biotech Products ETF Aggregate Rating and Price Target (2026)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.BBP Aggregate RatingModerate Buy 2.60Holdings in BBP have an aggregate rating of Moderate Buy based on 397 analyst ratings issued in the past year covering 25 companies (55.2% of the portfolio).BBP Aggregate Price Target$87.16High Prediction$87.16Average Prediction$87.16Low Prediction$87.16Holdings in BBP have an aggregate price target of $87.16 and a range of $87.16 to $87.16 covering 25 companies (55.2% of the portfolio).BBP Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy0 Buy rating(s)Moderate Buy18 Moderate Buy rating(s)Hold6 Hold rating(s)Reduce1 Reduce rating(s)Sell0 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by Virtus LifeSci Biotech Products ETF Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 25 BBP Holdings ExportWeight In ETFCompanyShare PriceMarketRank™Consensus Rating ScoreConsensus Price TargetPossible UpsideNumber of RatingsIndicator(s)ViewRatings4.96%IBRXImmunityBio$7.15+0.6%3.4736 of 5 stars2.71$14.20 98.7%7Positive NewsGap Up3.20%IOVAIovance Biotherapeutics$4.04-1.1%2.6632 of 5 stars2.30$8.43 108.9%10Positive NewsGap Down2.81%MRNAModerna$50.09+0.4%1.3316 of 5 stars1.83$36.60 -26.9%182.56%KALVKalVista Pharmaceuticals$27.003.1253 of 5 stars2.22$30.60 13.3%9News CoveragePositive NewsAnalyst UpgradeShort Interest Decrease2.51%AXSMAxsome Therapeutics$253.44-0.7%1.7426 of 5 stars2.95$256.79 1.3%21News Coverage2.49%NVAXNovavax$9.19+3.5%2.0623 of 5 stars2.10$12.13 32.0%10Gap Up2.46%LEGNLegend Biotech$35.23-1.8%4.2529 of 5 stars2.67$60.23 71.0%152.28%MIRMMirum Pharmaceuticals$103.12+3.8%4.1379 of 5 stars2.93$138.87 34.7%15Positive NewsAnalyst Forecast2.14%ROIVRoivant Sciences$30.08+0.1%2.3222 of 5 stars2.75$33.59 11.7%12Positive News2.13%TVTXTravere Therapeutics$52.36+0.6%1.4535 of 5 stars2.69$50.17 -4.2%13Analyst ForecastGap Down2.08%TGTXTG Therapeutics$49.00-1.1%2.3274 of 5 stars2.71$52.50 7.1%7Gap Down2.06%EXELExelixis$52.58-1.0%3.086 of 5 stars2.39$47.35 -9.9%23Positive News2.02%KRYSKrystal Biotech$316.79-0.4%2.7915 of 5 stars2.83$324.11 2.3%12Positive NewsGap Up2.00%LGNDLigand Pharmaceuticals$254.38-0.5%2.4475 of 5 stars2.88$257.71 1.3%8Insider Trade1.90%KNSAKiniksa Pharmaceuticals International$52.67+1.5%4.1396 of 5 stars2.89$60.86 15.5%9Positive News1.85%HALOHalozyme Therapeutics$71.20+2.4%4.2838 of 5 stars2.54$81.60 14.6%13Positive News1.81%BIIBBiogen$198.03-1.0%3.5885 of 5 stars2.55$217.26 9.7%291.80%BCRXBioCryst Pharmaceuticals$8.76+0.6%2.7099 of 5 stars2.75$20.70 136.4%121.78%UTHRUnited Therapeutics$546.58+0.1%4.2269 of 5 stars2.85$619.42 13.3%13Insider Trade1.76%NBIXNeurocrine Biosciences$158.14-1.0%3.8583 of 5 stars2.87$187.52 18.6%231.75%AMGNAmgen$355.65+0.1%3.8187 of 5 stars2.48$354.12 -0.4%31Positive NewsAnalyst Forecast1.72%ARWRArrowhead Pharmaceuticals$76.12+2.1%2.8023 of 5 stars2.75$87.80 15.4%12Positive News1.72%GILDGilead Sciences$124.45-0.9%4.9211 of 5 stars2.86$156.93 26.1%29Positive NewsAnalyst Revision1.70%BMRNBioMarin Pharmaceutical$56.18+0.4%4.5251 of 5 stars2.75$88.67 57.8%241.70%INCYIncyte$103.37-4.8%2.8537 of 5 stars2.32$105.10 1.7%22 This page (NYSEARCA:BBP) was last updated on 6/15/2026 by MarketBeat.com Staff. From Our PartnersThe 1934 playbookIn 1934, a legal government maneuver transferred billions in wealth overnight. Most Americans never saw it com...American Alternative | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredIs SpaceX really worth 1.78 Trillion?With SpaceX approaching a near-$2 trillion valuation, most investors are focused on the IPO itself - but analy...InvestPub | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredSpaceX is chump change compared to Elon’s $20T ‘iPhone’Early Apple investors saw peak gains as high as 7,537% after the iPhone launched. Now, multiple insider source...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Virtus LifeSci Biotech Products ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share Virtus LifeSci Biotech Products ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
